ADAMTS5 deficiency in mice does not affect cardiac function

The aggrecanase ADAMTS5 (A Disintegrin and Metalloproteinase with ThromboSpondin type 1 motifs, member 5) and the cleavage of its substrate versican have been implicated in the development of heart valves. Furthermore, ADAMTS5 deficiency was shown to protect against diet-induced obesity, a known risk factor for cardiovascular disease. Therefore, in this study, we investigated the potential role of ADAMTS5 in cardiac function using ADAMTS5-deficient (Adamts5(-/-)) mice and their wild-type (Adamts5(+/+)) counterparts exposed to a standard-fat or a high-fat diet (HFD). Eight-weeks-old Adamts5(-/-) and Adamts5(+/+) mice were exposed to each diet for 15 weeks. Cardiac function and electrophysiology were analyzed by transthoracic echocardiogram and electrocardiogram at the end of the study. Cleavage of versican, as detected by the appearance of the DPEEAE neo-epitope on western blotting with protein extracts, was defective in the heart of HFD-treated Adamts5(-/-) as compared with Adamts5(+/+) mice. ADAMTS5 deficiency led to statistically significant increases in diastolic posterior wall thickness (0.94 +/- 0.023 vs. 0.82 +/- 0.036 mm; P = 0.0056) and left ventricle volume (47 +/- 4.5 vs. 31 +/- 2.5 mu L; P = 0.0043) in comparison to Adamts5(+/+) mice, but only in animals on a HFD. Cardiac function parameters such as ejection fraction, fractional shortening, and stroke volume were unaffected by ADAMTS5 deficiency or diet. Electrocardiogram analysis revealed no ADAMTS5-specific changes in either diet group. Thus, in the absence of ADAMTS5, cleavage of versican in the cardiac extracellular matrix is impaired, but cardiac function, even upon exposure to a HFD, is not markedly affected.